J&J: applies for approval of Stelara in US

(CercleFinance.com) - Janssen, the pharmaceutical subsidiary of Johnson & Johnson, announced on Friday that it has filed an application with the Food and Drug Administration (FDA) for approval of Stelara for the treatment of juvenile psoriatic arthritis.


Juvenile arthritis is a group of rheumatic diseases that begins before the age of 16, combining arthritis, fever and rashes, and affects between 20 and 45 children out of every 100,000 in the United States, 5% of whom are affected by the psoriatic form of the disease.

Stelara, a monoclonal antibody, is already approved for the treatment of moderate to severe plaque psoriasis in adults and also for ulcerative colitis in adults.

The FDA's decision on juvenile psoriatic arthritis will come in 2022, Janssen said in a statement.


Copyright (c) 2021 CercleFinance.com. All rights reserved.